Frederik Marme

Frederik Marme

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 277 publications

Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study.

Constitutional BRCA1 Promoter Methylation in Patients With Ovarian Cancer: Results of the Observational AGO-TR1 Study.

Journal: JCO precision oncology

Published: June 12, 2026

Treatment and outcome of elderly patients with presumed early ovarian cancer in Germany: real-world observations from the quality-assurance program of the AGO Study Group.

Treatment and outcome of elderly patients with presumed early ovarian cancer in Germany: real-world observations from the quality-assurance program of the AGO Study Group.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: May 13, 2026

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: February 25, 2026

Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges.

Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges.

Journal: EClinicalMedicine

Published: December 23, 2025

Precision oncology without borders: the role of biobanking in integrating Africa's genetic diversity into global genomic research.

Precision oncology without borders: the role of biobanking in integrating Africa's genetic diversity into global genomic research.

Journal: NPJ precision oncology

Published: December 10, 2025

Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial.

Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial.

Journal: NPJ breast cancer

Published: December 04, 2025

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 03, 2025

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.

PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer-Results from the prospective PRAEGNANT registry.

Journal: NPJ breast cancer

Published: November 29, 2025

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: November 05, 2025

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial.

Journal: Breast cancer research and treatment

Published: October 24, 2025

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Journal: Nature communications

Published: September 09, 2025

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Journal: JCO precision oncology

Published: September 02, 2025

Showing 1-12 of 277

Last Updated: 09/26/2026